American Association for Cancer Research

Skip to Main Content

Table 1

Patient characteristics and DTH responses to E75

Patient no.	Tumor type	Age	Metastatic site(s)	TTP (wk)	No. of injections	PS^a	DTH skin test to E75 (mm induration)
1	BR	43	Liver	4	4	0	nd
2	BR	55	Liver, skin	8	5	1	nd
3	BR	41	Bone	1	1	1	nd
4	BR	32	Bone	8	5	0	−(<5)
5	BR	45	Lymph nodes, liver	4	4	0	+(5)
6	BR	39	Bone	16	7	0	+(7)
7	BR	51	Bone	16	7	0	+(10)
8	OV	77	Peritoneum	8	5	1	+(6)
9	BR	45	Bone, supraclavicular	12	6	0	nd
10	BR	61	Bone marrow^b	52	10	0	+(5)
11	BR	69	Skin	8	5	1	+(15)
12	BR	56	Lymph nodes	4	4	0	nd
13	BR	48	Lymph nodes	3	3	1	nd
14	BR	39	Bone	12	6	0	+(5)

Patient no.	Tumor type	Age	Metastatic site(s)	TTP (wk)	No. of injections	PS^a	DTH skin test to E75 (mm induration)
1	BR	43	Liver	4	4	0	nd
2	BR	55	Liver, skin	8	5	1	nd
3	BR	41	Bone	1	1	1	nd
4	BR	32	Bone	8	5	0	−(<5)
5	BR	45	Lymph nodes, liver	4	4	0	+(5)
6	BR	39	Bone	16	7	0	+(7)
7	BR	51	Bone	16	7	0	+(10)
8	OV	77	Peritoneum	8	5	1	+(6)
9	BR	45	Bone, supraclavicular	12	6	0	nd
10	BR	61	Bone marrow^b	52	10	0	+(5)
11	BR	69	Skin	8	5	1	+(15)
12	BR	56	Lymph nodes	4	4	0	nd
13	BR	48	Lymph nodes	3	3	1	nd
14	BR	39	Bone	12	6	0	+(5)

^a

PS, performance status; BR, breast; nd, not determined; OV, ovarian.

^b

Patient in remission after bone marrow transplantation before vaccination.